viewValiRx PLC

ValiRx updates on JV discussions and switches NOMAD

The company said it also expects to receive a tax credit shortly

ValiRx PLC - ValiRx updates on JV discussions and switches NOMAD
ValiRx is a clinical stage biotechnology company focused on cancer

ValiRx PLC (LON:VAL) said discussions to form a joint venture with investment firm Alpha Blue Ocean have not progressed beyond what it told the market in May and June.

As a result, any deal brokered “will be considered along with other opportunities”.

The update came as the drug developer said Novum was its new nominated adviser after SVS Securities was placed into administration.

ValiRx said it expects to receive a £400,000 R&D tax credit shortly. In the meantime, it continues to carefully manage its working capital position.

Quick facts: ValiRx PLC

Price: 7.75 GBX

Market: AIM
Market Cap: £1.39 m


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ValiRx PLC named herein, including the promotion by the Company of ValiRx PLC in any Content on the Site, the Company receives from said issuer...



Commercial discussions for ValiRx's lead cancer drug progressing 'rapidly'

George Morris, chief operations officer of ValiRx Plc (LON:VAL), tells Proactive's Andrew Scott commercial discussions to take their lead drug VAL 401 into a Phase III trial are progressing rapidly. He says by nature they're detailed and complex but he hopes they'll be completed shortly...

on 6/9/18

2 min read